Joseph Horrigan Joins AMO Pharma as Chief Medical Officer
Company further expands leadership team with new VP of Clinical Operations and Head of Pharmaceutical Science and Manufacturing
LONDON and PHILADELPHIA, April 18, 2016 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on debilitating diseases with limited or no treatment options, announced today the appointment of Joseph Horrigan as chief medical officer.
Dr. Horrigan comes to AMO Pharma with more than two decades of experience in the pharmaceutical industry and as a pediatric neuropsychiatrist. Prior to joining AMO Pharma, Dr. Horrigan held multiple leadership positions in pharmaceuticals and medical research. Most recently he led clinical development programs in neurodevelopmental disorders at Neuren Pharmaceuticals Limited. He also co-founded and led the company-wide Medicines for Children Advisory Network at GlaxoSmithKline and served as assistant vice president and head of medical research at Autism Speaks. He holds a medical degree from University of Rochester and is a clinical associate professor at the University of North Carolina.
In addition to Dr. Horrigan, AMO Pharma announced two additional appointments to the senior leadership team. The company has named Alison McMorn as vice president of clinical operations and Bernard Kiernan as head of pharmaceutical sciences and manufacturing. Dr. McMorn has an extensive background in managing global clinical development programs and most recently was director of clinical programs at Shire Pharmaceuticals. Mr. Kiernan has more than 20 years of experience in pharmaceuticals and joins the team from Shire Pharmaceuticals where he was director for product development in global pharmaceutical sciences.
"We are delighted to announce these additions to the AMO Pharma leadership team as the company continues to build momentum and advance our clinical stage development programs targeting new therapies for debilitating diseases including fragile X syndrome and myotonic dystrophy," said Mike Snape, chief executive officer and a founding director of AMO Pharma. "Dr. Horrigan, along with Dr. McMorn and Mr. Kiernan, bring a wealth of expertise in all phases of drug development and clinical research that will be an important asset for us as we continue to advance our current development programs and as we work to identify and acquire new assets for development in the years ahead."
To accommodate plans for continued expansion of U.S. operations, AMO Pharma also today announce plans to relocate its U.S. offices to 100 Berwyn Park, 850 Cassat Road in Berwyn, Pennsylvania in April.
About AMO Pharma
AMO Pharma is a biopharmaceutical company incorporated in February of 2015. The co-founder, Dr. Michael Snape, has extensive experience in senior scientific and operational roles in both large pharma and biotech companies spanning more than twenty five years, and has brought together a targeted and experienced senior management team with a proven track record of success in all phases of product development and acquisition. The company is working to identify and advance promising therapies for the treatment of serious and debilitating diseases in patient populations with significant areas of unmet need, including rare genetic diseases. AMO Pharma is currently advancing two investigational therapies for treatment of fragile X syndrome and myotonic dystrophy, and is in the process of licensing additional development-stage products in diverse areas including autism and other CNS disorders. For more information, please visit the AMO Pharma website at http://www.amo-pharma.com/.
Contacts
Corporate:
Lisa Wittmer, PhD
Chief Operating Officer
Head, Portfolio Development
AMO Pharma Ltd.
484.431.7991
lisa.wittmer@amo-pharma.com
Media:
Sara Zelkovic
Berry & Company Public Relations
212 253 8881
szelkovic@berrypr.com
Share this article